http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 crossref DOI: https://dx.doi.org/10.18535/jmscr/v7i9.65



Journal Of Medical Science And Clinical Research An Official Publication Of IGM Publication

Association of Microalbuminuria with IHD in Asymptomatic Type-2 Diabetes Mellitus Patients

Authors

Dr Sukh Chain¹, Dr Mansa Ram Saran^{2*}, Dr Rajendra Kumar Kasana³, Dr Vikash Kumar Agarwal⁴

^{1,4}Junior Specialist, ²Principal Specialist, ³Assistant Professor ^{1,2,4}Department of General Medicine, Govt. Shri Kalyan Hospital, Sikar, Rajasthan, India. ³Department of General Medicine, S.M.S. Medical College, Jaipur, Rajasthan, India ^{*}Corresponding Author

Dr Mansa Ram Saran

Abstract

Introduction: Recent studies have shown that presence of microalbuminuria in diabetic patients is associated with increased incidence of silent myocardial ischemia or asymptomatic coronary artery disease, which can be a cause of increased mortality due to cardiovascular diseases. Present study was conducted to see the association of microalbuminuria with IHD in asymptomatic type-2 diabetes mellitus patients.

Material and Methods: It was a comparative, analytic type of observational study carried out atDepartment of Medicine, S.M.S. Medical College, Jaipur, Rajasthan (India) from October 2011 to September 2012. After approval from institutional ethics committee 47 normoalbuminuric and 47 microalbuminuric asymptomatic type-2 diabetes mellitus patients were taken. Patients were asked for duration and symptoms of diabetes mellitus. Peripheral pulses were palpated to detect peripheral artery disease, foot examination was done to detect any ulcer, trophic changes or signs of ischaemia. Systolic and diastolic blood pressures, weight, BMI, waist circumference and waist-hip ratio were measured, Biochemical tests like fasting and post-prandial blood sugar, serum insulin, HbA1C, total lipid profile and urine examination were done. Treadmill test and transthoracic echocardiography was done. The data were statistically analysed using chi square test and unpaired 't' test. P-value < 0.05 was considered as statistically significant.

Results: No significant difference was observed in age, sex, weight, BMI, waist circumference, waist-hip ratio, history of smoking and all biochemical parameters except HDL and LDL cholesterol in both the groups. Duration of type-2 diabetes mellitus, mean systolic and diastolic blood pressures were significantly associated with microalbuminuria in asymptomatic type-2 diabetes mellitus patients. Overall, 34.04% patients with microalbuminuria had evidence of silent myocardial ischemia (SMI) as compared to 6.38% normoalbuminuric subjects which was statistically significant (P<0.05). Ejection fraction was comparable in both the groups.

Conclusion: Present study showed that there was increased occurrence of silent myocardial ischemia (SMI) in asymptomatic type-2 diabetes mellitus patients who had microalbuminuria as compared to those who had normoalbuminuria.

Keywords: Type-2 diabetes mellitus, Asymptomatic, Microalbuminuria, Normoalbuminuria, Ischemic heart disease.

Introduction

Type-2 diabetes mellitus (T2DM) is a heterogeneous group of disorders characterized by variable degrees of insulin resistance, impaired insulin secretion and increased glucose production. The prevalence of diabetes is rising worldwide with 285 million estimated cases in 2010 and expected to raise 366 million cases in 2030. Among these type-2 diabetes mellitus involves more than 90% of the cases of the disease.¹ India leads the world with largest number of diabetic subjects earning the dubious distinction of being termed the "diabetes capital of the world". According to the Diabetes Atlas 2006 published by the International Diabetes Federation, the number of people with diabetes in India are around 40.9 million and expected to rise to 69.9 million by 2025.²

In recent years studies have shown that in diabetic patients, the presence of microalbuminuria (MA) is associated with increased incidence of silent myocardial ischemia (SMI). It appears that microalbuminuria in type-2 diabetic patients is an indicator of vascular damage in general, and represents an independent risk factor for increased morbidity and mortality due to coronary artery disease (CAD).³ Coronary artery disease is the leading cause of death in patients with type-2 diabetes mellitus and is often asymptomatic or 'silent'. The cardiovascular mortality is increased two-fold in men and four-fold in women in the presence of T2DM, thus emphasizing the potential value of identifying high-risk asymptomatic individuals with diabetes.4,5

Silent myocardial ischemia (SMI) can be detected by using treadmill exercise testing. SMI has been defined as exercise-induced ST-segment depression in the absence of CAD symptoms. Prevalence of microalbuminuria (MA) is observed in 15% to 25.9% patients of type-2diabetes mellitus and is associated with a doubling of the risk of early death, mainly from CAD. The presence of underlying silent myocardial ischemia and microalbuminuria are significantly related to future CAD events in asymptomatic patients with type-2 diabetes mellitus, therefore SMI and MA could be of predictive value in riskstratification.^{5,6} The purpose of our study was to find out the association of presence of microalbuminuria in asymptomatictype-2 diabetes mellitus patients with development of silent myocardial ischemia.

Material and Methods

It was a hospital based, comparative, analytic study, carried out in Department of Medicine, S.M.S. Medical College, Jaipur (Rajasthan) from October 2011 to September 2012. Prior approval from institutional ethics committee was obtained. Total94 type-2 diabetes mellitus patients between age group 40-60 years and asymptomatic for ischemic heart disease (47 normoalbuminuric and 47 microalbuminuric) were recruited in the study after taking informed written consent. Patients with urinary tract infection, haematuria, heart failure, febrile illness, severe hyperglycaemia, severe hypertension, pregnant women, seriously ill patients or on life supporting measures, known case of CAD, any renal disease due to causes other than type-2 diabetes mellitus, with abnormal resting ECG and contraindications to exercise stress test were excluded from the study.

Selected patients were evaluated clinically by history taking including age, sex, duration of diabetes and clinical examination including general physical examination, assessment of vitals and systemic examination. Patients were asked for symptoms of diabetic complications such as visual disturbances, diplopia, dyspnoea, chest pain, orthopnoea, numbness, paraesthesia, weakness in limbs, pedal swelling, intermittent claudication and foot ulcers. Patients were thoroughly evaluated for pallor, edema, presence of acanthosis nigricans, xanthoma and xanthelasma. Blood pressure was measured in right arm in supine position. Those with systolic blood pressure \geq 140 mmHg or diastolic blood pressure >90 mmHg or on antihypertensive medications were considered as hypertensive. All peripheral pulses were palpated to detect peripheral artery disease. Foot examination was thoroughly done to

detect any ulcer, trophic changes or signs of ischaemia.

Anthropometric parameters like weight, height, BMI, waist circumference, hip circumference, waist-hip ratio (WHR) were measured. Height was measured to the nearest 0.5 cm without shoes. Each participant stood in such a way so that the Frankfort plane (a line connecting the superior border of the external auditory meatus with the infraorbital rim) was horizontal (i.e. parallel to the floor). Weight was measured after removal of shoes and was recorded to the nearest 0.1 kg. BMI was calculated as weight $(kg)/height (m)^2$. Those with a BMI of 25.0–29.99 kg/ m^2 were classified as overweight, whilst those with a BMI \geq 30.0 kg/ m² were classified as obese.BMI between 18.50 -24.99 kg/ m² being considered as normal. While those with BMI <18.5 kg/m² are considered Waist undernourished. circumference was using a measuring measured tape, with measurements made halfway between the lower border of the ribs and the iliac crest in a horizontal plane. Hip circumference was measured at the widest point over the buttocks. For each of waist and hip circumference, two measurements to the nearest 0.5 cm were recorded. If the variation between the measurements was greater than 2 cm, a third measurement was taken. The mean of the two closest measurements was calculated. Men with a waist circumference 94-101.9 cm and women with a waist circumference 80-87.9 cm were classified as overweight, whilst men with a waist circumference ≥ 102.0 cm and women with a waist circumference >88.0 cm were classified as obese WHR was obtained by dividing the mean waist circumference by the mean hipcircumference. Men with a WHR 0.90-0.99 and women with a WHR 0.80-0.84 were classified as overweight, whilst men with a WHR ≥ 1.00 and women with a WHR ≥ 0.85 were classified as obese.

After overnight fasting for 10-12 hours blood of the patients was sent for investigations such as fasting blood sugar, serum insulin, HbA1C and total lipid profile. Post-prandial blood sugar (PPBS) was measured 2 hours after meal. Plasma glucose was measured with glucose oxidase technique on automated auto analyzer. Glycated haemoglobin was measured by chromatography analyzer and a value of less than 7% was taken to indicate good glycaemic control. Total lipid estimated by sulfo-phosphovainilline assay- a colorimetry-based method. Total cholesterol was estimated by an enzymatic method using cholesterol esterase cholesterol oxidase and peroxidise. HDL cholesterol was estimated by a reagent-based assay using automated clinical chemistry analyzer. LDL cholesterol was measured using an enzymatic colorimetric technique. Triglyceride was estimated by GOD/POD method. Serum creatinine was measured by a test which is based on the peroxidase like activity of a copper creatinine complex that catalyses the reaction of disopropylbenzene dihydroperoxide and tetra methyl benzidine. The resulting colour range from orange through green and blue.

Urine routine examination from fasting urine sample was done to measure microalbuminuria for every patient. Albumin is normally present in urine at concentrations of less than 20 mg/L. Microalbuminuria is indicated with results of 20– 200mg/L. Creatinine is normally present in urine at concentration of 10–300mg/ dl(0.9– 26.5mmol/L).

Albumin is normally present in urine at concentration of less than 30 mg albumin/gm creatinine (3.4mg albumin/mmol creatinine). Microalbuminuria is indicated at a ratio of 30–300mg/gm (3.4–33.9 mg/mmol) (Abnormal) and clinical albuminuria at a ratio of >300mg/gm (>33.9mg/mmol) (highly abnormal). Patients with high abnormal values i.e. macroalbuminuria were excluded from study. For microalbuminuria clinitek 100 test was used. This test is based on dye binding using a high affinity sulfonaphthalin dye. At a constant pH, development of blue colour is due to albumin.

Patients were subjected to exercise treadmill testing using Bruceprotocol. Twelve lead ECG

and blood pressure measurement were done at rest, before starting test. Heart rate and blood pressure were measured at the end of each stage and every 2 minutes during the recovery phase. Hypotension was considered if there was a decrease in systolic blood pressure 10 mm of Hg or BP falls below the resting value. The interruption criteria used was horizontal or down sloping ST segment depression ≥1mm, ST elevation ≥ 1 mm compared to baseline ECG, ≥10% decrease in systolic blood pressure, no increase in heart rate or presence of bradycardia, blood pressure above 250/150mm Hg, severe angina, development of severe arrhythmia, attaining target heart rate and being too tired to sustain the test. Exercise test was considered positive in case of horizontal or down sloping ST segment depression ≥1mm, development of angina during the test, and $\geq 10\%$ decrease in systolic blood pressure.

Transthoracic echocardiography was done in the left lateraldecubitus position by the same cardiologist to see LV function and any regional wall motion abnormality or any abnormality suggesting ischemic heart disease.

Data thus collected were entered in Microsoft Excel 2010worksheets in the form of master chart. Qualitative data were expressed in the form of percentage and proportions. Quantitative data were expressed in the form of means and standard deviations. Chi Square test and unpaired 't' test were used to see association. A p-value <0.05 was considered statistically significant.

Results

The patients of type-2 diabetes mellitus, who were free from symptoms of ischemic heart disease like chest pain, dyspnoea on exertion, fatigue and orthopnoea were considered asymptomatic. 47 such asymptomatic patients of type-2 diabetes mellitus without microalbuminuria were taken as group-A and similar number of asymptomatic patients of type-2 diabetes mellitus with microalbuminuria were taken as group-B. Patients of both sexes from various medical wards and OPD were taken for study.

Majority of patients in group-A were in age group of 56-60 years (36.17%), followed by 51-55 years (27.65%), whereas in group-B majority of patients were in age group of 51-55 years (40.42%), followed by 56-60 years (27.65%). Males were 61.7% in group-A while 53.19% in group-B. Majority of subjects were non-smokers in both the groups, only 14.89% subjects in group-A and 17.02% subjects in group-B were smokers. Overweight and obesity were more common in microalbuminuria group (group-B) as compared to normoalbuminuria group (group-A) according to BMI, waist circumference and waist-hip ratio criteria (Table-1).

Age, sex, weight, obesity criteria like, BMI, waist circumference and waist-hip ratio and personal history of smoking were not significantly different (P>0.05) in both the groups suggesting good randomization and comparability (Table-1 &2).

In the present study 29.78% subjects were hypertensive in group-B and 25.53% in group-A and this difference was not significant (P>0.05, Table-3) but mean systolic and mean diastolic blood pressures in both groups were significantly different (P<0.05, Table-2). All biochemical parameters (fasting blood sugar, post-prandial blood sugar, serum insulin, HbA1C, total lipids, total cholesterol and triglycerides) did not shown the significant difference except HDL and LDL. Left ventricular ejection fraction (Table-2) and left ventricular diastolic dysfunction (Table-3) were also not significantly different in both the groups.

The present study revealed that duration of type-2 diabetes mellitus was significantly associated with microalbuminuria. Silent myocardial ischemic was significantly high (34.04%)in microalbuminuria group comparison in to normoalbuminuria group (6.38%) (P<0.05, Table-3). Chest pain was developed in 93.75% patients of SMI during treadmill test in microalbuminuria group while it was observed only in 66.67% patients of SMI in normoalbuminuria group (Table-4).

2019

Table-1:	Distribution	of	subjects	according	to
demograp	hic and perso	nal	profile (N	(=94)	

Parameter	Group-A (Normoalbuminuri a) n (%)	Group-B (Microalbuminur ia) n (%)	P-value [*]	
Age:			•	
40-45	9(19.14)	6(12.76)		
46-50	8(17.02)	9(19.14)	0.605*	
51-55	13(27.65)	19(40.42)	0.695*	
56-60	17(36.17)	13(27.65)		
Gender:			•	
Male	29(61.70)	25(53.19)	0.531#	
Female	18(38.29)	22(46.80)	0.551	
Smoking:				
Yes	7 (14.89)	8 (17.02)	1.000	
No	40 (85.10)	39 (82.97)	1.000	
BMI (kg /m ²):				
Normal (18.50 -	17 (36.17)	8 (17.02)		
24.99)		• ()	0.109	
Overweight (25.0– 29.99)	5 (10.63)	7 (14.89)		
Obese (≥30.0)	25 (53.19)	32 (68.09)		
Waist Circumferen	ce:		•	
Normal (m= <94cm, f= <80cm)	17 (36.17)	7 (14.89)		
Over weight (m=94-101.99cm, f=80-87.99cm)	6 (12.76)	7 (14.89)	0.059	
Obese (m= ≥ 102 cm, f= ≥ 88 cm)	24 (51.06)	33 (70.21)		
Waist Hip Ratio:				
Normal				
(m= <0.90, f=	16 (34.04)	7 (14.89)		
<.80)				
Over weight (m= 0.90-0.99, f= 0.80-0.84)	6 (12.76)	8 (17.02)	0.097	
Obese (m= ≥1.00, f= >0.85)	25 (53.19)	32 (68.09)		
<u>~ (),())</u>	l	l		

Chi square test

Table-2:Comparative analysis of variousparameters in both groups (N=47 in each group)

			1/
Parameter	Group-A (Normoalbuminuria) (Mean±SD)	Group-B (Microalbuminuria) (Mean±SD)	P- value [*]
Weight (in kg)	73.39 ±11.55	76.28 ±10.64	0.210
BMI(kg/mt ²)	27.91 ±4.53	29.15±3.51	0.141
Duration (in years)	3.76 ± 2.76	5.48 ±3.61	0.011
SBP(mm of Hg)	122.34±10.33	132.08±13.87	< 0.01
DBP(mm of Hg)	80.42±5.86	84.85±6.2	< 0.01
FBS	126.08±27.19	130.28±23.26	0.423
PPBS	187.32±35.60	198.76±26.67	0.081
Serum insulin	10.11±4.34	10.73±4.22	0.484
HbA1C	7.35±1.47	8.11±1.58	0.018
Total Lipid	550.38±99.34	558.23±116.51	0.726
Total Cholesterol	167.94±37.88	181.51±41.56	0.101
HDL	44.66±6.17	40.96±4.57	0.001
LDL	95.83±33.05	111.28±37.04	0.036
Triglycerides	137.15±47.95	147.02±42.70	0.295
LVEF(%)	61.17±3.60	60.32±4.66	0.325
*Unnaired 't' test			

Unpaired 't' test

Table-3: Association of various parameters withmicroalbuminuriainasymptomaticT2DMpatients

-		C D		
Parameter	Group-A (Normoalbuminuria) n (%)	Group-B (Microalbuminuria) n (%)	P- value [*]	
Duration of T2	DM:			
0 -5 Years	38 (80.85)	26 (55.31)		
6-10 Years	7 (14.89)	16 (34.04)	0.029	
11-15 Years	2 (4.25)	5 (10.63)		
Hypertension:				
Yes	12 (25.53)	14 (29.78)	0.010	
No	35 (74.46)	33 (70.21)	0.818	
Left ventricula	r diastolic dysfunction:			
Yes	3 (6.38)	5 (10.64)	0.712	
No	44 (93.62)	42 (89.36)	0.712	
Silent myocard	ial ischemia:	•		
Yes	3 (6.38)	16 (34.04)	0.002	
No	44 (93.62)	31 (65.96)	0.002	

*Chi square test

Table-4:	Distribution	of	symptoms	during
treadmill t	est in patients v	with	SMI	

Symptoms	Group-A (Normoalbuminuria)		Group-B (Microalbuminuria)	
	N=3	%	N=16	%
Chest pain	2	66.67	15	93.75
Dyspnoea	3	100	9	56.25
Fatigue	1	33.33	4	25
Dizziness	0	0	3	18.75

Discussion

It was observed in the present study that microalbuminuric (MA) patients had higher of BMI than normoalbuminuric values (NA)diabetic patients (29.15 \pm 3.51 kg/m² MA and 27.91 \pm 4.53 kg/m² in NA) but the difference was not significant (P>0.05). Similar results were observed by Hussein and Strak⁷ (BMI 27.5 \pm 6.3 kg/m²in MA, 27 \pm 5.18 kg/m²NA) while contrary results were observed by Rutter et al⁵ (30 \pm 4.8 kg/m² vs. 27.1 \pm 4.8 kg/m² respectively, P<0.05). The present study revealed that about 55.31% microalbuminuric patients and 80.85% normoalbuminuric patients had diabetes mellitus from 0-5 years. A significant difference was seen between the two groups in regard to duration of type-2 DM (5.48 \pm 3.61 years in MA and 3.76 \pm 2.76 years in NA, P<0.05). Hussein and Strak⁷, Yildirimturk et al⁸ and Rani et al⁹ also found similar results.

Hypertension (29.78% vs. 25.53%) and smoking habit (17.02% vs. 14.89%) were more in microalbuminuric group than normoalbuminuric group, but this difference was statistically not

(P>0.05). Similar significant results were observed by Hussein and Strak⁷ and Yildirimturk et al⁸ in their studies. Although significant difference was seen in both groups with regard to mean systolic BP (132.08 \pm 13.87 mm Hg vs.122.34 \pm 10.33 mm Hg respectively, P<0.05) and mean diastolic BP ($84.85 \pm 6.2 \text{ mm Hg vs.} 80.42 \pm 5.86$ mm Hg respectively, P<0.05). Rani et al⁹ also significant observed difference а in microalbuminuric and normoalbuminuric subjects with regard to systolic BP and diastolic BP (P<0.05) while Rutter et al⁵ observed in their study that systolic BP was significantly higher in microalbuminuric subjects than normoalbuminuric (P < 0.05). Hussein and Strak⁷ showed that diastolic BP was significantly higher in microalbuminuric patients than normoalbuminuric (P<0.05). Yildirimturk et al⁸ showed no significant difference between microalbuminuric and normoalbuminuric type-2 diabetic subjects with regard to systolic and diastolic BP (P>0.05).

In present study patients with microalbuminuria had higher values of fasting blood sugar as compared to their normoalbuminuric counterparts $(146.15 \pm 30.20 \text{ mg/dl vs.} 126.08 \pm 27.19 \text{ mg/dl})$ respectively) and the difference between two groups was significant (P<0.001). A statistically significant difference with regard to post-prandial also observed between blood sugar was microalbuminuric and normoalbuminuric type-2 diabetic subjects (208 \pm 36.18 mg/dl vs. 187.32 \pm 35.60 mg/dl respectively, P<0.001). Earlier, Rutter et al⁵(10.6 \pm 3.9 mmol/l in MA, 9.4 \pm 3.6mmol/l in NA, P>0.05), Hussein and Strak⁷ $(152.7 \pm 26 \text{ mg/dl} \text{ in MA}, 131 \pm 19.5 \text{ mg/dl} \text{ in})$ NA, P<0.05)and Mattock et al¹⁰(10.5 mmol/l in MA, 8.89 mmol/l in NA, P<0.05)found higher values of fasting plasma glucose in microalbuminuric type-2 diabetic subjects as compared to normoalbuminuric type-2 diabetic subjects in their studies. Yildirimturk et al⁸ observed low values of fasting plasma glucose in microalbuminuric type-2 diabetic subjects (141.3 \pm 29.5 mg/dl) as compared to normoalbuminuric type-2 diabetic counterparts ($142 \pm 40.6 \text{ mg/dl}$) in

their study, but the difference was not significant (P>0.05).

No significant difference with regard to serum insulin was observed in microalbuminuric and normoalbuminuric type-2 diabetic subjects in the present study $(10.73 \pm 4.22 \text{ vs. } 10.11 \pm 4.34)$ respectively, P>0.05), although significantly higher values (P<0.05) of glycated haemoglobin (HbA1c) were seen in microalbuminuric type-2 diabetic subjects $(8.11 \pm 1.58 \text{ gm}\%)$ as compared to normoalbuminuric type-2 diabetic subjects $(7.35 \pm 1.47 \text{ gm}\%)$. Similarly, Rutter et al⁵ (8.7 ± 1.6 gm% in MA, 7.9 ± 1.3 gm% in NA), Yildirimturk et al⁸ (7.5 \pm 2.0 gm% vs. 6.9 \pm 1.4 gm% respectively), Rani et al⁹ (9.0 \pm 2.3 gm% vs. 8.0 ± 2.1 gm% respectively) and Mattock et al¹⁰(9.7 gm% vs. 8.3 gm% respectively) were also observed the higher values of glycated haemoglobin (HbA1c) in microalbuminuric group as compared to normoalbuminuric group. The difference between microalbuminuric type-2 diabetic subjects and normoalbuminuric type-2 diabetic subjects were significant (P<0.05) in studies by Rutter et al⁵, Rani et al⁹ and Mattock et al¹⁰ while it was not significant (P>0.05) in study by Yildirimturk et al⁸.

Present study suggested that total lipids were higher in microalbuminuric group compared with normoalbuminuric group $(550.38 \pm 99.34 \text{ mg/dl in})$ NA vs. $558.23 \pm 116.51 \text{ mg/dl}$ in MA), but the difference was statistically not significant (P>0.05). The values of total cholesterol were also higher in microalbuminuric group (181.51 ± 41.56) mg/dl) as compared to normoalbuminuric group $(167.94 \pm 37.88 \text{ mg/dl})$ and again the difference was statistically not significant (P>0.05). Similar results were observed by previous authors like, Rutter et al^5 (5.6 mmol/l in MA, 5.5 mmol/l in NA), Hussein and Strak⁷ (205 \pm 40.8 mg/dl in MA, 181.4±28.7 mg/dl in NA) Yildirimturk et al⁸ $(207.7 \pm 44.6 \text{ mg/dl in MA}, 194.7 \pm 31.6 \text{ mg/dl in})$ NA) and Mattock et al $^{10}\,(6.74\,\pm\,0.26$ mmol/dl in MA, 6.05 ± 0.12 mmol/dl in NA) in their studies where they observed the higher values of total cholesterol in microalbuminuric group as

compared to normoalbuminuric group. The difference between microalbuminuric type-2 diabetic subjects and normoalbuminuric type-2 diabetic subjects were significant (P<0.05) in studies by Hussein and Strak⁷ and Mattock et al¹⁰ while it was not significant (P>0.05) in studies by Rutter et al⁵ and Yildirimturk et al⁸.

The values of LDL cholesterol in present study were also significantly higher in microalbuminuric group as compared to normoalbuminuric group $(111.28 \pm 37.4 \text{ mg/dl vs.} 95.83 \pm 33.05 \text{ mg/dl})$ respectively, P<0.05). Similar results were found by Yildirimturk et al⁸ (125.6±32.0 vs. 113.5±27.5 respectively)in their study but the difference was not significant (P>0.05).The HDL was significantly low in microalbuminuric group as compared to normoalbuminuric group (40.96 \pm 4.57 vs. 44.66 \pm 6.17 respectively) in this study. This difference was statistically significant (P<0.01). Rutter et $al^{5}(1.0 \pm 0.3 \text{ mmol/l in MA},$ 1.2 ± 0.4 mmol/l in NA), Hussein and Strak⁷(47.6 \pm 13 mg/dl vs. 48.6 \pm 14.7 mg/dl respectively) and Rani et al⁹ $(38.8 \pm 9.3 \text{ mg/dl vs.} 39.2 \pm 10.2 \text{ mg/dl}$ respectively) also seen the same results in their studies, but the difference was statistically not significant (P>0.05) in these studies. The values of triglycerides in present study were also higher in microalbuminuric group as compared to normoalbuminuric group (147.02±42.70 mg/dl vs. 137.15±47.95mg/dl respectively) but the difference was not significant (P>0.05). Earlier, Rutter et al⁵, Yildirimturk et al⁸(145 \pm 59.6 mg/dl vs. 143.5 ± 76.5 mg/dl respectively) and Rani et $al^{9}(156.1 \pm 80.4 \text{ mg/dl vs.} 153.4 \pm 104.4 \text{ mg/dl})$ respectively) also observed higher values of triglycerides in microalbuminuric subjects as compared to normoalbuminuric subjects in their studies and the difference was not significant statistically (P>0.05).

The subjects with microalbuminuria had lower values of LVEF compared with normoalbuminuria $(60.32\pm4.66\%$ in MA, $61.17\pm3.60\%$ in NA), but this difference was not statistically significant (P>0.05). Yildirimturk et al⁸ also observed lower values of LVEF in microalbuminuric diabetic

subjects than in normoalbuminuric subjects in their study ($63.1\pm1.4\%$ in 12 MA patients vs. $64.4\pm2.3\%$ in 38 NA patients, P>0.05).

In the present study, it was found that 8 patients had some degree of left ventricular diastolic dysfunction, 3 (6.38%) in NA group and 5 (10.64%) in MA group but this difference was not significant statistically (P>0.05). Yildirimturk et al⁸ found no significant difference between microalbuminuric and normoalbuminuric subjects with regard to left ventricular diastolic function indices in their study.

The present study revealed that 6.38% patients (3 out of 47) in normoalbuminuric group and 34.04% patients (16 out of 47) in microalbuminuric group had silent myocardial ischemia (SMI). In normoalbuminuric group out of 3 treadmill test positive subjects, one was male and 2 were female while in microalbuminuric group out of 16 subjects, 11 were male and 5 were females. The difference was significant (P<0.01). Hussein and Strak⁷ detected SMI in 30% microalbuminuric and 6.6% normoalbuminuric type-2 diabetic subjects in their study. Yildirimturk et al⁸ observed 75% microalbuminuric and 31.6% normoalbuminuric type-2 diabetic subjects in their study. Zabeen et al¹¹ found 42% microalbuminuric and 32% normoalbuminuric type-2 diabetic subjects had silent myocardial ischemia in their study. Rutter et al⁵ observed that 52% subjects (45 out of 86) had SMI. Out of these 45, treadmill test positive patients, 28 were from microalbuminuric group and 17 were from normoalbuminuric group. Thus, all these found statistically significant difference between two groups with regard to SMI (P<0.05). In their follow up study, they showed that future CAD events were significantly associated with SMI (P<0.05) and microalbuminuria (P<0.05). They also observed that subjects with both SMI and MA were more likely to develop CAD events than others (P < 0.01). In the present study it was observed that no patient had regional wall motion abnormality in both groups.

2019

Conclusion

Present study showed that silent myocardial ischemia was more common in microalbuminuric group as compared to normoalbuminuric group. The presence of underlying silent myocardial ischemia and microalbuminuria are significantly related to future CAD events in asymptomatic patients with type-2 diabetes, therefore estimation of microalbuminuria in asymptomatic T2DM patients can play a good role in prediction of CAD events which can be prevented.

Conflict of Interest: Nil

References

- Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May; 27(5):1047–1053.
- Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type2 diabetes: Indian scenario. Indian J Med Res. 2007 Mar;125(3):217-30.
- 3. George I, Melpomeni P, Phivi R, Michael C, Christos P, Georgia C et al. The occurrence of microalbuminuria and retinopathy with cardiovascular risk factors: reliable predictors of asymptomatic coronary artery disease in type 2 diabetes. Hormones, 2004;3(3):198-203.
- Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrson's principles of internal medicine. 18th ed. New York: Ma Graw Hill Education; 2011.
- 5. Rutter MK, Wahid ST, MaComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients 2 with type diabetes. J Am Col Cardiol. 2002 Jul; 40(1):56-61.

- Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes:a role for the glomerular endothelium? Diabetologia. 2008 May;51(5):714–725.
- Hussein AZF, Strak SK. Silent myocardial ischemia and microalbuminuria in asymptomatic type-2 diabetic patients. Pak J Med Sci. 2006;22(2):116-121.
- Yildirimtürk O, Kiliçgedik M, Tuğcu A, Aytekin V, Aytekin S. The relationship of microalbuminuria with left ventricular functions and silent myocardial ischemia in asymptomatic patients with type 2 diabetes. Turk Kardiyol Dern Ars. 2009 Mar;37(2):91-7.
- Rani PK, Raman R, Gupta A, Pal SS, Kulothungan V, Shrama T. Albuminuria and Diabetic Retinopathy in Type 2 Diabetes Mellitus Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 12). Diabetol Metab Syndr. 2011,3(9):1-8.
- Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM et al. Microalbuminuria and Coronary Heart Disease in NIDDM: an incidence study. Diabetes. 1998 Nov;47(11):1786–92.
- 11. Zabeen S, Hoque MM, Rahman MR.
 Silent Myocardial Ischemia and its Association with Microalbuminuria in Type 2 Diabetes Mellitus. BSMMU J. 2012 Jan; 5(1):42-45.